Skip to main content
. 2019 Dec 2;40(1):52–61. doi: 10.1177/0272989X19889905

Table 1.

Sample Characteristics (N = 101)

Characteristic Value
Patient age in years, mean (SD) 60.6 (11)
TiOS score, mean (SD) 4.1 (0.6)
Consultation duration, mean (SD), min 00:28:03 (00:12:29)
OPTION-12 sum score, mean (SD) 15.5 (11.6)
Education, n (%)
 High 29 (29)
 Intermediate 51 (50)
 Low 21 (21)
Marital status, n (%)
 Single 35 (35)
 In a relationship 66 (65)
Has children, n (%) 84 (83)
Preferred level of involvement in decision making, n (%)
 Patient driven 39 (39)
 Shared 41 (41)
 Oncologist driven 21 (21)
Consultations with university hospital oncologists, n (%) 20 (20)
Consultations with use of Adjuvant! online, n (%) 60 (59)
Tumor size, n (%)
 0–20 mm 58 (58)
 ≥21 mm 42 (42)
 Missing 1
Tumor stage,an (%)
 Stage I 43 (43)
 Stages II and III 58 (57)
Tumor positive lymph nodes present, n (%) 33 (33)
Positive estrogen receptor (ER) status (n = 96), n (%) 84 (88)
 Missing 5
Positive progesterone receptor (PR) status (n = 95), n (%) 73 (77)
 Missing 6
Positive HER2/neu receptor status, n (%) 7 (7)
 Missing 5
Triple negative (i.e., ER/PR/HER2/neu negative; n = 96), n (%) 10 (10)
 Missing 5
Surgery (n = 96), n (%)
 Breast conserving 51 (53)
 Mastectomy 45 (47)
 Missing 5
Has received radiotherapy (n = 96), n (%) 54 (56)
Missing 5
Treatment(s) discussed during the consultation, n (%)
 Chemotherapy only 12 (12)
 Endocrine therapy only 18 (18)
 Chemotherapy and endocrine therapy 70 (70)
Chemotherapy decision (yes; n = 94), n (%) 53 (57)
 Missing 7
Endocrine therapy decision (yes; n = 93), n (%) 79 (85)
 Missing 8

OPTION-12, 12-item Observing Patient Involvement In Decision Making scale; TiOS, Trust in Oncologist Scale.

a

TNM staging source: American Joint Committee on Cancer. Cancer Staging Manual. 7th ed. Chicago, IL: American College of Surgeons, 2015.